ライフサイエンスコーパス: dose ratio

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 , tacrolimus formulations were switched (1:1 dose ratio).

2 acy by increasing the tumor-to-normal tissue dose ratio.

3 ted to the alternate formulation at a 1:1 mg dose ratio.

4 ethal doses of ionizing radiation, radiation dose ratio, 3:1 (hypoxia:air).

5 After conversion using a 1:1 dose ratio, an individualized approach to the management

6 ned-agent therapy as a function of the tumor-dose ratio and the fraction of activity contributed by e

7 is a promising approach to improve absorbed dose ratios and achieve high durable remission rates wit

8 stimates of dose profiles and peak-to-valley dose ratios at the position of the targeted and traverse

9 The THW-to-rhTSH organ absorbed dose ratio averaged over 5 organs for the first 3 patien

10 The absorbed dose ratio between marrow, liver and spleen volumes and

11 iodide, therefore, yielding a lower absorbed dose ratio between NIS-transfected and -nontransfected c

12 Absorbed dose ratios between these sites and the whole body were

13 DZR at 5:1, 10:1, and 20:1 dose ratios caused a dose-dependent decrease in the MTS

14 residence time, and improved tumor-to-kidney dose ratio compared with (177)Lu-DOTATATE and (90)Y-OPS2

15 se was calculated as a function of the tumor-dose ratio, defined as the (90)Y-DOTATOC tumor dose per

16 tic/antagonistic (S/A), dose-level (DL), and dose-ratio (DR) dependency interactions.

17 Tumor/red marrow dose ratios exceeded 3:1 for most lesions.

18 A higher tumor-to-organ dose ratio for (177)Lu-DOTA-JR11 than for (177)Lu-DOTATA

19 evaluated to compute the predicted-to-actual dose ratio ([Formula: see text]) in tumor volumes (TVs)

20 At a dose ratio greater than seven, the two drugs showed no d

21 A higher tumor-to-kidney absorbed dose ratio might be achieved by optimizing the amount of

22 Level-to-dose ratios obtained within 4 weeks after delivery refle

23 A DZR:DOX dose ratio of 10:1 is recommended based on studies in pa

24 or-dose increase of 68% occurred for a tumor-dose ratio of 2.57, using 92% of the maximum tolerated (

25 At a prednisone-to-dexamethasone dose ratio of less than seven, dexamethasone (6-18 mg/m(

26 ncreased activity in ALL cells in vitro, the dose ratio of the two drugs that exerted equivalent cyto

27 l dose profiles and calculate peak-to-valley dose ratios of 30-40 for cell cultures and approximately

28 ed dose of (90)Y, with tumor-to-normal organ dose ratios of 7:1 for liver and 15:1 for lung and kidne

29 ttenuating the cardiomyopathy caused by DOX, dose ratios of DZR:DOX capable of providing total or nea

30 nnitol reactivity, expressed as the response dose ratio (RDR: max % fall in FEV1 /cumulative dose), w

31 s (p = 0.02), as well as tumor-to-red marrow dose ratios, than other cancer types.

32 o-dose-limiting-organ (bone marrow) absorbed dose ratio, that is, the therapeutic index, was higher i

33 the tumor-to-kidney and tumor-to-bone marrow dose ratio was 1.1-7.2 times higher.

34 The dexrazoxane:doxorubicin dose ratio was 10:1, and the cumulative protocol-specifi

35 The overall tumor-to-kidney dose ratio was approximately 24% and 32% higher for (177

36 therapy increased tumor dose when the tumor-dose ratio was greater than 0.67 and less than 5.93.

37 The tumor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)L

38 Tumor-to-lung, -kidney and -liver radiation dose ratios were 7.4:1, 5.3:1 and 2.6: 1, respectively.

39 Tumor-to-normal organ dose ratios were increased about 8- to 11-fold compared

40 Serum-level-to-dose ratios were lower during pregnancy than the postpar

41 The mean tumor-to-marrow absorbed dose ratio when using the optimized PRIT schema was 63:1

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。